InvestorBrandNetwork (IBN) Content Platform

HeartBeam (NASDAQ: BEAT), announced the issuance of two new U.S. patents that strengthen its intellectual property portfolio and support the company’s expansion in remote cardiac diagnostics. The new patents protect core technologies behind HeartBeam’s compact, cable-free 3D ECG device and its rhythm analysis algorithm capable of identifying arrhythmias through continuous signal input. 

The 3D ECG device, which uses chest and finger electrodes to collect high-fidelity signals in three non-coplanar directions, is designed for on-demand symptom recording and 12-lead ECG synthesis. Its software is currently under FDA review, backed by data from the VALID-ECG pivotal study. The rhythm algorithm works across cardiac monitoring systems and triggers targeted data collection during abnormal rhythm detection, enhancing diagnostic precision.

With 20 issued patents and 34 additional filings, HeartBeam continues to solidify its position at the forefront of digital cardiac care innovation, with future plans to incorporate AI capabilities for enhanced diagnostic accuracy.

To view the full press release, visit https://ibn.fm/iJ35f

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com .

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

NanoViricides, Inc. (NYSE American: NNVC) asserts that its antiviral candidate NV-387 is uniquely positioned to address rising global threats from emerging COVID-19 variants like NB1.8.1 “Nimbus” and evolving strains of Bird Flu, including highly pathogenic genotypes identified in the U.S. and Cambodia. NV-387, which has completed Phase I trials without adverse events, is designed as an oral, broad-spectrum antiviral that mimics heparan sulfate structures—an invariant viral binding mechanism—making viral escape unlikely. The company reports NV-387 significantly outperformed leading antivirals like Remdesivir, Tamiflu(R), and Xofluza in animal models of lethal lung infections. NanoViricides emphasized its U.S.-based cGMP manufacturing readiness and ability to stockpile the drug, noting NV-387’s potential to deliver rapid patient recovery and natural immunity while avoiding the limitations of vaccine-dependent strategies.

To view the full press release, visit https://ibn.fm/QOvWs

About NanoViricides Inc.

NanoViricides is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide(TM) class of drug candidates and the nanoviricide(TM) technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. NanoViricides’ lead drug candidate is NV-387, a broad-spectrum antiviral drug that the company plans to develop as a treatment of RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is currently focused on advancing NV-387 into Phase II human clinical trials. NanoViricides’ other advanced candidate is NV-HHV-1 for the treatment of Shingles. The company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. NV-CoV-2 (“API NV-387”) is the company’s nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is NanoViricides’ other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. For more information about the company, visit www.NanoViricides.com.

NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Newton Golf Company (NASDAQ: NWTG), a technology-forward golf brand, announced that PGA TOUR Champions star Miguel Ángel Jiménez has officially joined the company and will play its Newton Fast Motion shaft, which he used to win the Principal Charity Classic. Jiménez’s playoff win in Iowa marked his 16th PGA TOUR Champions title and the second Tour victory for Newton’s Motion shaft line. The Fast Motion shaft, launched in April 2025, features advanced carbon fiber construction and proprietary performance technologies aimed at delivering speed, control, and consistency for golfers with moderate swing speeds. The win further validates Newton’s impact across professional tours, following Doug Barron’s 2024 major win at the Regions Tradition.

To view the full press release, visit https://ibn.fm/PuvqD

About Newton Golf

At Newton Golf, we harness the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, our rebranding reflects our commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of our design process, we create precision-engineered golf clubs that deliver unmatched stability, control, and performance. Our mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

• Solowin Holdings offers diversified exposure to both traditional financial services and next-generation digital assets.
• The company leverages regulatory licenses in Hong Kong to serve global high-net-worth and institutional investors.
• Solowin delivers brokerage, investment banking, asset management, and Web3 services across its Solomon Win and Solomon VA+ platforms, offering clients seamless access to both traditional and digital financial solutions.
• Strategic investments, such as its $10M contribution to AlloyX, an Asia-based stablecoin infrastructure firm, highlight Solowin’s proactive role in fintech innovation.
• Led by seasoned executives with decades of capital markets experience, the company is positioned for sustained global expansion.

Solowin (NASDAQ: SWIN) is a versatile financial services provider focused on delivering comprehensive investment solutions from traditional finance as well as decentralized finance to high-net-worth and institutional clients. Operating through its wholly owned subsidiary, Solomon JFZ (Asia) Holdings Limited, Solowin is licensed by the Hong Kong Securities and Futures Commission and offers access to a full suite of financial services through its secure, one-stop electronic platform, Solomon Win.

Driven by a vision to create a modernized financial services infrastructure, especially to bridging traditional finance and the Web3 technology, Solowin has prioritized innovation, agility, and client-first experiences. The firm has experienced robust growth, aligning itself with evolving capital markets and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SWIN are available in the company’s newsroom at https://ibn.fm/SWIN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Rezolve Ai (NASDAQ: RZLV) is an industry leader in AI-powered solutions, specializing in enhancing customer engagement, operational efficiency, and revenue growth. The Brain Suite delivers advanced tools that harness artificial intelligence to optimize processes, improve decision-making, and enable seamless digital experiences.

For more information, visit the company’s website at: www.rezolve.com

To view IBN’s virtual coverage of the 15th Annual London Conference, visit https://ibn.fm/RothLondon2025

About InvestorBrandNetwork’s Virtual Coverage

IBN, a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the companies participating in ROTH’s 15th Annual London Conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

• Women make up roughly 28% of on-course golfers in the United States, a historic high.
• The global golf equipment market is booming, generating an estimated $25.5 billion in 2024 and projected to grow at nearly 6% annually.
• Newton Golf’s lighter shaft is engineered to weigh less than previous versions while maintaining precision, stability and distance.

A surge in women’s golf participation is reshaping the industry, drawing fresh energy and opportunity to equipment manufacturers. Newton Golf Company (NASDAQ: NWTG) recently released the perfect piece of equipment for this dynamic market — a lighter shaft option, designed to deliver premium performance for golfers of all levels, from weekend enthusiasts to tour professionals, who are widely adopting the new shaft in competition.

Women now make up roughly 28% of on-course golfers in the United States, a historic high, with female participation climbing 41% since 2019 to reach 7.9 million players in 2024 (https://ibn.fm/d1HkS). Notably, younger women are entering the sport in record numbers through recreational and social formats such…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Quantum BioPharma (NASDAQ: QNTM) has announced that the first multiple sclerosis patient has been scanned in a collaborative study with Massachusetts General Hospital to validate a novel PET imaging technique for tracking myelin integrity. The study uses the tracer [18F]3F4AP, developed by MGH’s Dr. Pedro Brugarolas, which has shown high sensitivity to demyelinated lesions. Scanning took place on a new GE Signa PET-MR scanner, enabling simultaneous PET and MRI imaging to enhance precision. The technique may become a vital biomarker for evaluating drug responses aimed at remyelination, including Quantum’s own candidate Lucid-21-302.

To view the full press release, visit https://ibn.fm/WITS5

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD(TM) and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Foremost Clean Energy (NASDAQ: FMST) (CSE: FAT) announced a strengthened financial position with over $4.5 million raised through recent warrant and option exercises by insiders and investors. The added capital supports ongoing exploration and drilling initiatives amid rising uranium prices and a forecasted structural supply deficit. Concurrently, the company is extending its strategic investor awareness campaign with LFG Equities Corp., aimed at highlighting Foremost’s unique positioning in the nuclear energy supply chain and its Nasdaq-listed exposure to Canada’s Athabasca Basin alongside Denison Mines Corp. (NYSE American: DNN). The expanded campaign, running through Dec. 31, 2025, will deploy digital outreach, influencer engagement, and social media content across North America.

To view the full press release, visit https://ibn.fm/qKmQ7

About Foremost Clean Energy Ltd.

Foremost Clean Energy, assuming the effectiveness of the transaction, will be an emerging North American uranium exploration company with interests in 10 prospective properties spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin. As global demand for decarbonization accelerates, the need for nuclear power is crucial. Foremost expects to be positioned to capitalize on the growing demand for uranium through discovery in a top jurisdiction with the objective to support the world’s energy-transition goals. Alongside its exploration partner Denison, Foremost will be committed to a strategic and disciplined exploration strategy to identify resources by testing drill–ready targets with identified mineralization along strike of recent major discoveries. Foremost also maintains a secondary portfolio of significant lithium projects at different stages of development spanning over 50,000 acres across Manitoba and Quebec. For more information about the company, visit www.ForemostCleanEnergy.com.  

NOTE TO INVESTORS: The latest news and updates relating to FMST are available in the company’s newsroom at http://ibn.fm/FMST

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Lantern Pharma (NASDAQ: LTRN) announced a remarkable clinical outcome in its Phase 2 HARMONIC(TM) trial, with a 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) achieving a durable complete response following treatment with LP-300 in combination with standard chemotherapy. The patient, who had previously failed three lines of therapy including Keytruda(R), radiation, and Tagrisso(R), initially saw a 57% tumor reduction and later achieved full resolution of lung and adrenal lesions. Nearly two years after treatment initiation, the patient remains progression-free and has experienced no clinically significant adverse reactions across 21 cycles. This sustained response underscores the potential of LP-300, developed using Lantern’s RADR(R) AI platform, to address a critical unmet need in never-smoker NSCLC patients who have exhausted targeted kinase therapy options—a group representing a growing, underserved segment with limited approved treatments.

To view the full press release, visit https://ibn.fm/R0c2m

About Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company’s proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Tonix Pharmaceuticals (NASDAQ: TNXP) presented new data at the 2025 Annual European Congress of Rheumatology (EULAR) in Barcelona supporting TNX-102 SL, its sublingual cyclobenzaprine formulation for fibromyalgia. The poster highlighted results from the RESILIENT Phase 3 trial showing statistically significant, sustained pain reduction over 14 weeks, along with improved sleep and favorable tolerability. Designed to bypass first-pass liver metabolism, TNX-102 SL achieved higher nighttime cyclobenzaprine levels and lower norcyclobenzaprine accumulation compared to oral formulations, potentially enhancing long-term efficacy. With a Prescription Drug User Fee Act (PDUFA) goal date of Aug. 15, 2025, TNX-102 SL could become the first new fibromyalgia therapy in 15 years.

To view the full press release, visit https://ibn.fm/XLzee

About Tonix Pharmaceuticals Holding Corp.

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s priority is to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) this month for TNX-102 SL, a product candidate for which two statistically significant phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL was generally well tolerated in the phase 3 program. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix recently announced that the U.S. Department of Defense (“DoD”), Defense Threat Reduction Agency (“DTRA”) awarded it a contract for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Maryland. The company’s Good Manufacturing Practice (“GMP”)-capable advanced manufacturing facility in Dartmouth, Maryland, was purpose-built to manufacture TNX-801, and the GMP suites are ready to be reactivated in case of a national or international emergency. Tonix’s development portfolio is focused on central nervous system (“CNS”) disorders. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R)(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. For more information about the company, please visit www.TonixPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

As the powersports and recreational watercraft industries experience a notable upswing, Massimo Group (NASDAQ: MAMO) is taking a proactive approach through domestic manufacturing, strategic partnerships, and product diversification—initiatives that position the company to capitalize on emerging opportunities. Fueled by growing consumer enthusiasm for outdoor recreation and the multi-purpose appeal of vehicles like those in Massimo’s lineup, the global powersports market—valued at $37.96 billion in 2023—is expected to reach $60.51 billion by 2032. Founded in 2009 and headquartered in Garland, Texas, Massimo Motor has aligned itself with these trends through a broad product line that includes UTVs, ATVs, e-bikes and pontoon boats, catering to both recreational enthusiasts and commercial users. A strong focus on innovation and quality remains central to the company’s long-term growth strategy.

To view the full article, visit https://ibn.fm/Dhgw1

About Massimo Group

Massimo Group is a manufacturer and distributor of powersports vehicles and pontoon boats. Founded in 2009, Massimo Motor believes it offers some of the most value packed UTVs, off-road, and on-road vehicles in the industry. The company’s product lines include a wide selection of farm and ranch tested utility UTVs, recreational ATVs, and Americana style mini-bikes. Massimo Marine manufactures and sells pontoon and tritoon boats with a dedication to innovative design, quality craftsmanship, and great customer service. Massimo Group is also developing electric versions of UTVs, golf-carts and pontoon boats. The company’s 376,000 square foot factory is in the heart of the Dallas / Fort Worth area of Texas in the city of Garland. For more information, visit massimomotor.com and massimomarine.com.

NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https://ibn.fm/MAMO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

RedCloud Holdings (NASDAQ: RCT) announced that CEO and Co-Founder Justin Floyd will attend the ROTH 15th Annual London Conference, taking place at the Four Seasons Hotel London at Park Lane. The event provides a platform for RedCloud to engage with investors and industry stakeholders in an international setting.

To view the full press release, visit https://ibn.fm/VPEqF

About RedCloud

RedCloud has developed and operates the RedCloud trading platform (the “Platform”), that facilities trade of everyday consumer supplies of fast-moving consumer goods (“FMCG”) products across business supply chains. RedCloud believes its Platform solves a decades old problem of how to unlock and enable access to key purchase and sales data between brands, distributors and retailers in high growth consumer markets. Through RedCloud’s Platform, retailers are enabled to use data driven insights backed by artificial intelligence (“AI”) to help make faster and easier business-to-business (“B2B”) purchases and inventory decisions from brands and distributors by breaking down complex purchasing behaviors of large product inventory catalogues.

For more information, visit the company’s website at www.redcloudtechnology.com

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

• FAVO recently secured an $8 million equity investment to fund growth and accelerate its plan to uplist to the Nasdaq Capital Market
•  The company voluntarily converted all super voting Series C Preferred Shares, simplifying its capital structure and improving governance transparency
• With SMBs turning away from traditional banks, FAVO’s revenue-based lending platform meets rising demand for fast, flexible funding solutions

As inflationary pressures and elevated interest rates strain traditional financing channels, small and medium-sized businesses (“SMBs”) are increasingly seeking alternative funding sources to maintain liquidity and drive growth. Bank approval rates for SMB loans have dropped significantly – from 83% in 2019 to just 68% in 2022 – creating a wide credit gap. This shift has accelerated demand for alternative lending options like merchant cash advances (“MCAs”) and revenue-based financing (“RBF”), which offer faster, more flexible access to capital.

Within this expanding sector, FAVO Capital (OTC: FAVO) stands out as a fintech-driven private credit firm built specifically to meet the evolving needs of underserved SMBs. The company has a multi-prong digital approach, including the development of an advanced digital platform designed to enhance client…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Cybin (NYSE American: CYBN) (NEO: CYBN) issued a corporate update emphasizing continued momentum in its clinical pipeline, including the advancement of its lead candidate CYB003 into Phase 3 development. CEO Doug Drysdale underscored the growing regulatory clarity around psychedelic therapeutics and expressed optimism that Cybin’s IP portfolio and clinical strategy position the company to help transform mental health treatment. Drysdale also noted favorable shifts in regulatory sentiment as a key tailwind for expediting the review process.

To view the full press release, visit https://ibn.fm/s99dx

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Tonix Pharmaceuticals (NASDAQ: TNXP) a fully-integrated biotechnology company with marketed products and late-stage development candidates, announced the appointment of James “Jim” Hunter to its Board of Directors, effective June 12. Hunter previously served as Executive Vice President, Commercial, where he built the Company’s commercial subsidiary, Tonix Medicines, and led its entry into the migraine market. CEO Dr. Seth Lederman cited Hunter’s operational insight and commercial expertise as key assets as the company prepares for a potential launch of TNX-102 SL for fibromyalgia later this year.

To view the full press release, visit https://ibn.fm/9wBqi

About Tonix Pharmaceuticals Holding Corp.

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s priority is to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) this month for TNX-102 SL, a product candidate for which two statistically significant phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL was generally well tolerated in the phase 3 program. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix recently announced that the U.S. Department of Defense (“DoD”), Defense Threat Reduction Agency (“DTRA”) awarded it a contract for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Maryland. The company’s Good Manufacturing Practice (“GMP”)-capable advanced manufacturing facility in Dartmouth, Maryland, was purpose-built to manufacture TNX-801, and the GMP suites are ready to be reactivated in case of a national or international emergency. Tonix’s development portfolio is focused on central nervous system (“CNS”) disorders. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R)(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. For more information about the company, please visit www.TonixPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases. The company recently announced its financial results for the first quarter of 2025 as well as accomplishments representative of Soligenix’s continued commitment to advance its pipeline of therapeutic candidates, focusing on areas with significant unmet medical needs.

“Our strategic focus remains on advancing our clinical programs, and we anticipate several significant development milestones,” said Soligenix CEO and president Christopher J. Schaber, PhD. “These include top-line results in 2026 from our actively enrolling phase 3 confirmatory study of HyBryte(TM) [synthetic hypericin] for early-stage cutaneous T-cell lymphoma (‘CTCL’). Furthermore, we expect to report top-line results in the second half of this year from our ongoing phase 2 studies of SGX945 (dusquetide) in Behçet’s disease and SGX302 (synthetic hypericin) in mild-to-moderate psoriasis.”

To view the full article, visit https://ibn.fm/V8xDT

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For further information, visit the company’s website at www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

FAVO Capital (OTC: FAVO) is developing a digital lending platform to address the persistent financing gap faced by underserved small and medium-sized businesses (“SMBs”). Traditional banks often deny credit to these businesses due to outdated underwriting models, creating a market ripe for disruption. FAVO is responding with fast, flexible, and accessible capital solutions for SMBs that are often overlooked. With more than 5.5 million new business applications filed in the U.S. last year alone, FAVO’s tech-driven approach is well-positioned to serve this growing segment with real-world financing solutions.

To view the full article, visit https://ibn.fm/V7zaB

About FAVO Capital Inc.

FAVO Capital is a rapidly growing alternative finance company headquartered in Fort Lauderdale, Florida. The company offers personalized alternative finance solutions to emerging, small and medium-sized businesses. “FAVO” is “Honeycomb” in Latin – The Honeycomb (Hexagon) is the most efficient shape in the universe. FAVO intends to be efficient, flexible and durable. For more information visit www.FavoCapital.com.

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

• Italian football club Juve Stabia finished 5th in Serie B and reached the semifinals of the Serie A promotion playoffs, recording the highest market value increase in Serie B since March 2025.
• Brera now holds a 38.46% stake in the club, with full FIGC approval for the acquisition.
• Attendance surged, with one match nearly selling out the 7,100-seat stadium, as Juve Stabia games have gained international attention, with broadcasts in the U.S., U.K., and Canada.
• A €5 million (US$5.85 million) subsidy was announced by the Campagna Region for Romeo Menti Stadium refurbishment.

Brera Holdings (NASDAQ: BREA), an Ireland-based international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) strategy, is celebrating the strong performance of its Italian football portfolio club, SS Juve Stabia, which reached the semifinals of the Serie A promotion playoffs after finishing fifth in Italy’s Serie B regular season (https://ibn.fm/jhXA6).

Brera agreed to acquire a controlling interest in Juve Stabia in December 2024. Its most recent step in the acquisition was completed in February 2025, giving Brera a 38.46% stake at present. The move received formal approval from the Italian Football Federation (“FIGC”), underscoring compliance with national…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI) announced that CEO Amir Reichman will participate in the BIO International Convention 2025, taking place June 16–19 in Boston. The company will present recent strategic, operational, and financial milestones, including its rapid CDMO business growth and progress on its nanobody pipeline. Scinai recently secured $1.38 million in funding via its Standby Equity Purchase Agreement with Yorkville Advisors, boosting capital without warrants or additional dilution. The company reaffirmed 2025 CDMO revenue guidance of $2 million and targets breakeven in 2026.

To view the full press release, visit https://ibn.fm/MLWIb

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

• The private credit market has experienced remarkable growth over the past decade, evolving from a niche segment to a cornerstone of the financial ecosystem
• FAVO Capital offers a range of financing options, including revenue-based funding and merchant cash advances
• The company’s impact is reflected in its impressive track record of supporting 10,000-plus small businesses, deploying more than $138 million in capital nationwide

In today’s increasingly fragile economic landscape, small and mid-sized businesses (“SMBs”) face mounting challenges in securing the funding necessary for growth and sustainability. Traditional banks, constrained by stringent regulations and risk-averse policies, often fall short in meeting the unique financial needs of these enterprises. This funding gap has paved the way for alternative financing solutions, with private credit emerging as a vital lifeline. Among the key players in this space is FAVO Capital (OTC: FAVO).

The private credit market has experienced remarkable growth over the past decade, evolving from a niche segment to a cornerstone of the financial ecosystem. According to Preqin, private credit assets under management have surged from $500 billion in 2013 to more than $1.7 trillion in 2025, reflecting a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Silvercorp Metals (TSX: SVM) (NYSE American: SVM)  has filed an updated mineral resource estimate for its Condor gold project in Ecuador. The filing follows its May 12, 2025, announcement and includes the “Independent Technical Report for the Condor Project, Ecuador,” prepared by SRK Consulting (Canada) Inc., with an effective date of Feb. 28, 2025.

To view the full press release, visit https://ibn.fm/KRqia

About Silvercorp

Silvercorp is a Canadian mining company producing silver, gold, lead, and zinc with a long history of profitability and growth potential. The Company’s strategy is to create shareholder value by 1) focusing on generating free cash flow from long life mines; 2) organic growth through extensive drilling for discovery; 3) ongoing merger and acquisition efforts to unlock value; and 4) long term commitment to responsible mining and ESG.

NOTE TO INVESTORS: The latest news and updates relating to SVM are available in the company’s newsroom at https://ibn.fm/SVM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Vivakor (NASDAQ: VIVK), a vertically integrated energy infrastructure and environmental services company, is focused on the transportation, storage, reuse, and remediation of oilfield fluids and waste. “The company operates a large-scale oilfield trucking fleet, serving key U.S. energy regions, enabling end-to-end solutions for the handling of crude oil and produced water. Through long-term contracts and strategic asset positioning, Vivakor delivers critical services to upstream energy operators seeking efficient and environmentally responsible operations,” reads a recent article. “Vivakor’s vision is to become a leader in sustainable energy logistics and remediation by combining innovative infrastructure with environmentally conscious practices. The company’s integrated model allows it to optimize the flow and treatment of petroleum-based materials across the value chain. By owning and operating both the logistics and remediation components, Vivakor is well-positioned to support an evolving energy ecosystem.”

To view the full article, visit https://ibn.fm/lbszd

About Vivakor Inc.

Vivakor is an integrated provider of sustainable energy transportation, storage, reuse, and remediation services, operating one of the largest fleets of oilfield trucking services in the continental United States. Its corporate mission is to develop, acquire, accumulate, and operate assets, properties, and technologies in the energy sector. Vivakor’s integrated facilities assets provide crude oil and produced water gathering, storage, transportation, reuse, and remediation services under long-term contracts. 

Once operational, Vivakor’s oilfield waste remediation facilities will facilitate the recovery, reuse, and disposal of petroleum byproducts and oilfield waste products.

NOTE TO INVESTORS: The latest news and updates relating to VIVK are available in the company’s newsroom at https://ibn.fm/VIVK

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) is currently valued at ~19× forward earnings—below the S&P 500 average of 22.5×—making it the cheapest of the “Magnificent Seven” and sparking discussion about whether its low price represents value or a potential trap. While its search dominance is under siege from AI challengers like ChatGPT and regulatory pressure could force asset divestitures, Alphabet also boasts strong assets—YouTube, Google Cloud, and Waymo—plus a $70 billion share buyback plan and reliable dividend yield that suggest hidden upside.

As of 5:00 p.m. ET on June 11, 2025, Alphabet stock (NASDAQ: GOOG) is trading at $179.13, down $0.88 (―0.49%), with intraday highs and lows between $181.88 and $178.85, on volume of 9.97 million shares.

To view the full article, visit https://ibn.fm/5PTH6

About Alphabet Inc.

Alphabet Inc., parent of Google, leads global search, digital advertising, cloud computing, and video platforms. With a focus on innovation through YouTube, Google Cloud, and autonomous-vehicle unit Waymo, Alphabet is executing a $70 billion share buyback and pays a modest dividend. Its diverse business model and strong cash flows position it for both growth and value creation.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Meta Platforms (NASDAQ: META) is reportedly preparing to invest approximately $14.8 billion for a 49% stake in Scale AI, a leading provider of data-labeling services critical to AI model training. As part of the deal, Scale AI’s CEO, Alexandr Wang, will join Meta to spearhead a new “superintelligence” lab alongside a 50person research team personally led by Mark Zuckerberg. The move comes in the wake of underperforming Llama 4 and delays to the “Behemoth” flagship AI model, making this Meta’s boldest strategic pivot in AI to date.

On the regulatory front, U.S. antitrust authorities—particularly the FTC and DOJ—are scrutinizing even minority investments under Clayton Act provisions, raising questions about whether Meta can sidestep past regulatory hurdles related to Instagram and WhatsApp. Proponents, however, note that Scale AI’s projected revenue doubling to over $2 billion in 2025 and early investor gains may help justify the deal.

As of June 11, 2025, Meta stock (NASDAQ: META) is trading at $700.45, down $1.95 (–0.28%) on the day. Intraday trading has ranged between $697.72–$708.54, on volume of approximately 4.8 million shares.

To view the full article, visit https://ibn.fm/5FZde

About Meta Platforms Inc.

Meta Platforms Inc., formerly Facebook, is an American multinational technology conglomerate headquartered in Menlo Park, California. It operates leading social platforms—Facebook, Instagram, WhatsApp, and Threads—and is increasingly investing in AI infrastructure. The company is currently facing an ongoing U.S. antitrust trial concerning its historic acquisitions of Instagram and WhatsApp.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Snap (NYSE: SNAP) announced at the Augmented World Expo 2025 that its next-generation AR glasses, dubbed Specs, will be launched to consumers in 2026. These ultra‑lightweight, standalone wearable computers boast see-through lenses overlaying digital content on the real world and come powered by on-device AI. Snap OS is also receiving major upgrades: deep integrations with OpenAI and Google’s Gemini, a depth-module API for 3D spatial anchoring, automated speech recognition in over 40 languages, developer solutions like a Fleet Management app, Guided Mode, and Guided Navigation—geared to enable shared AR experiences, productivity, and streaming directly through the glasses.

Snap Inc. (NYSE: SNAP) shares are trading at $8.67, up 2.12% for the day. Intraday trading has ranged from $8.46 to $8.95, on volume of approximately 20.3 million shares.

To view the full article, visit https://ibn.fm/pJsJo

About Snap Inc.

Snap Inc. is a leading camera and social media company, best known for Snapchat and its AR lens platform. Founded in 2011 and headquartered in Santa Monica, California, Snap has invested over $3 billion in AR hardware and software development. The company empowers a global network of more than 400,000 developers who have created over 4 million AR Lenses, contributing to billions of daily experiences. Snap continues to innovate at the intersection of artificial intelligence, computer vision, and immersive computing.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

NVIDIA (NASDAQ: NVDA) ignited a surge in quantum computing stocks after CEO Jensen Huang declared the industry had reached an “inflection point,” reversing prior skepticism about near-term applications. Speaking at the VivaTech conference, Huang said NVIDIA’s Cuda-Q platform is now enabling practical quantum-classical hybrid solutions in fields like chemistry and finance. The announcement boosted investor confidence in the space, sending shares of Quantum Computing Inc. (NASDAQ: QUBT), IonQ Inc. (NASDAQ: IONQ), Rigetti Computing Inc. (NASDAQ: RGTI), D-Wave Quantum Inc. (NYSE: QBTS), and Arqit Quantum Inc. (NASDAQ: ARQQ) notably higher in trading.

As of the most recent session, NVIDIA shares (NASDAQ: NVDA) are trading at $143.13, down 0.58%, while sector peers posted intraday gains ranging from 2% to 14% as momentum spilled across the quantum ecosystem.

To view the full article, visit https://ibn.fm/g7qNz

About NVIDIA Corp.

NVIDIA Corporation is a global leader in GPU and AI computing technologies, powering data centers, gaming platforms, and emerging industries including autonomous vehicles and quantum computing. The company’s Cuda-Q initiative aims to accelerate hybrid quantum workloads by integrating classical GPU capabilities with next-generation quantum systems. Founded in 1993, NVIDIA is headquartered in Santa Clara, California.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Broadcom (NASDAQ: AVGO) shares climbed after the company posted strong fiscal Q2 results, with a 20% year-over-year revenue increase to $15 billion, fueled by a 46% surge in AI-related chip sales totaling $4.4 billion. While forward guidance was more reserved, the standout AI performance overshadowed broader concerns, prompting analyst upgrades and renewed investor confidence in Broadcom’s long-term positioning in the data infrastructure and AI markets.

As of the most recent trading session on June 11, 2025, Broadcom stock (NASDAQ: AVGO) is trading at $251.36, up 2.75% from the prior close.

To view the full article, visit https://ibn.fm/5zVDP

About Broadcom Inc.

Broadcom Inc. is a global technology leader that designs, develops, and supplies semiconductor and infrastructure software solutions. The company’s product portfolio serves critical markets including data center, networking, broadband, wireless, storage, and industrial. Broadcom is headquartered in Palo Alto, California.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

ESGold (CSE: ESAU) (OTCQB: ESAUF) CEO and Director Paul Mastantuono joined the Exploring Mining Podcast to discuss the company’s fully permitted, near-production Montauban Project in Quebec. In the interview, Mastantuono highlighted ESGold’s strategic shift toward surface-accessible resources like tailings and low-cost ore bodies, positioning the company for accelerated production without the typical drilling-heavy approach of junior miners. He also covered recent leadership additions, share structure updates—with fewer than 75 million shares outstanding—and the company’s push to finalize concentration testing ahead of first gold production at Montauban. 

To view the full press release, visit https://ibn.fm/LnTqL 

About ESGold Corp. 

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) (FSE: Z7D) is a fully permitted, pre-production resource company at the forefront of clean mining and exploration innovation. With proven expertise in Quebec, the Company is advancing its projects toward production and feasibility while delivering long-term value through sustainable resource recovery and exploration. ESGold’s flagship Montauban property, located 80 kilometers west of Quebec City, serves as a model for responsible mining practices, combining near-term production with district-scale discovery potential. 

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data showing its lead candidate, Telomir-1, significantly reversed neurological, liver, and kidney symptoms in a genetic animal model of Wilson’s disease, a rare disorder caused by copper accumulation. In zebrafish mimicking human pathology, Telomir-1 delivered a 4- to 5-fold reduction in tremors, normalized movement behaviors, cut liver copper levels by 50%, improved organ histopathology, and restored key liver biomarkers to wild-type levels. The drug also improved survival under copper stress, supporting its copper-regulating mechanism. Telomir plans to file its first IND by year-end and begin human trials in 2026.

To view the full press release, visit https://ibn.fm/ZqxNm

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a preclinical stage pharmaceutical company seeking to lead development in longevity science in both humans and animals. The company is focused on the development of Telomir-1, a novel small molecule designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir’s goal is to develop, gain regulatory approval for and commercialize Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life. For more information about the company, visit the website www.Telodx.com.

NOTE TO INVESTORS: The latest news and updates relating to TELO are available in the company’s newsroom at https://ibn.fm/TELO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN